Literature DB >> 25323056

Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years.

Chee-Seng Yee1, Li Su2, Veronica Toescu2, Richard Hickman2, Deva Situnayake2, Simon Bowman2, Vernon Farewell2, Caroline Gordon2.   

Abstract

OBJECTIVE: The aim of this study was to describe the outcomes and predictors for development of damage in a large inception cohort of SLE patients.
METHODS: This was a prospective longitudinal study of a cohort of SLE patients. SLE patients were included if they were recruited within 3 years of achieving the fourth ACR criterion for SLE. Data were collected on disease activity, damage and treatment. Information on death was provided by the Office for National Statistics. The censoring date for analysis was 31 December 2010. A standardized mortality ratio was calculated. Poisson regression was used to determine the incidence rate for damage accrual. Multistate Markov modelling was used to determine predictors for development of damage.
RESULTS: There were 382 patients (92.4% females, 51.6% Caucasian, 22% South Asian, 20.7% Afro-Caribbean) with 12 072 assessments and total follow-up of 2958 patient-years. There were 300 items of damage (in 143 patients) and 37 deaths. The overall standardized mortality ratio was 2.0 (95% CI 1.5, 2.8) and the most common causes of death were infection (37.8%), cardiovascular (27%) and malignancy (13.5%). The predictors for damage accrual were higher prior damage, older age at diagnosis, active disease, systemic corticosteroid exposure and CYC exposure. Patients were more likely to develop new damage earlier in their disease than later. Ethnicity was not predictive of damage accrual or death in this cohort.
CONCLUSION: SLE patients have premature mortality. Active disease, corticosteroid exposure and CYC exposure were independently associated with the development of damage. Damage accrual is more likely to occur in early disease.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  SLE; damage; disease activity; inception cohort; mortality; therapy

Mesh:

Substances:

Year:  2014        PMID: 25323056     DOI: 10.1093/rheumatology/keu412

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  29 in total

1.  Predictors of damage accrual in systemic lupus erythematosus: a longitudinal observational study with focus on neuropsychological factors and anti-neuronal antibodies.

Authors:  Milena Mimica; Ignacio Barra; Rocío Ormeño; Patricia Flores; Jorge Calderón; Oslando Padilla; Marcela Bravo-Zehnder; Alfonso González; Loreto Massardo
Journal:  Clin Rheumatol       Date:  2019-07-31       Impact factor: 2.980

2.  Changing trends in mortality in systemic lupus erythematosus? An analysis of SLE inpatient mortality at University Hospital Coventry and Warwickshire NHS Trust from 2007 to 2016.

Authors:  Himashi Anver; Shirish Dubey; James Fox
Journal:  Rheumatol Int       Date:  2019-09-30       Impact factor: 2.631

Review 3.  Epidemiology and management of healthcare-associated bloodstream infections in non-neutropenic immunosuppressed patients: a review of the literature.

Authors:  Nursel Calik Basaran; Sibel Ascioglu
Journal:  Ther Adv Infect Dis       Date:  2017-10-17

4.  Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil.

Authors:  Jordana Vaz Hendler; Lucian de Souza; Daniele Corrêa de Freitas Zernow; Juliano Guimarães; Thiago Bertotto; Carla Forgiarini Saldanha; João Carlos Tavares Brenol; Odirlei André Monticielo
Journal:  Clin Rheumatol       Date:  2017-06-26       Impact factor: 2.980

5.  A retrospective study of joint infections in patients with systemic lupus erythematosus.

Authors:  Lin Qiao; Dong Xu; Yan Zhao; Xiaofeng Zeng; Fengchun Zhang
Journal:  Clin Rheumatol       Date:  2017-07-08       Impact factor: 2.980

Review 6.  Hypertension in connective tissue disease.

Authors:  Qiang Luo; Yiwen Zhang; Xiaoqian Yang; Li Qin; Han Wang
Journal:  J Hum Hypertens       Date:  2022-05-03       Impact factor: 3.012

7.  Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry.

Authors:  Laura Plantinga; S Sam Lim; Rachel Patzer; William McClellan; Michael Kramer; Mitchel Klein; Stephen Pastan; Caroline Gordon; Charles Helmick; Cristina Drenkard
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-03       Impact factor: 4.794

8.  Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus.

Authors:  Yoko Wada; Hisashi Hasegawa; Takako Saeki; Satoshi Ito; Takeshi Kuroda; Masaaki Nakano; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2017-10-25       Impact factor: 2.801

9.  Tuftsin-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model.

Authors:  A Shemer; S Kivity; O Shovman; T Bashi; O Perry; A Watad; D Ben-Ami Shor; A Volkov; I Barshack; N L Bragazzi; A Krule; M Fridkin; H Amital; M Blank; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2018-08       Impact factor: 4.330

10.  Understanding the impact of systemic lupus erythematosus on work amongst South Asian people in the UK: An explorative qualitative study.

Authors:  Mandeep Ubhi; Shirish Dubey; Caroline Gordon; Tochukwu Adizie; Tom Sheeran; Kerry Allen; Rachel Jordan; Steven Sadhra; Jo Adams; Rashmika Daji; John A Reynolds; Kanta Kumar
Journal:  Lupus       Date:  2021-06-06       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.